Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET

Company Participants

Sarah Mathieson - SVP, Corporate Affairs

David Cory - President & CEO

Ingrid Choong - SVP-Clinical Development

Eldon Mayer - Chief Commercial Officer

Sriram Ryali - CFO

Colleen Craig - VP-Metabolic Diseases

Conference Call Participants

Maurice Raycroft - Jefferies

Robert Hazlett - BTIG

Michael Higgins - Ladenburg Thalmann

Operator

[Starts Abruptly] and business update conference call. At this times, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this call will be recorded.

I would now like to introduce Sarah Mathieson, Senior Vice President, Corporate Affairs at Eiger. You may begin.

Sarah Mathieson

Thank you. Good afternoon, everyone, and thank you for joining us today. Welcome to our quarterly financial results and business update call. We issued a press release earlier this afternoon with our Q2 financial results, which is also available on our website at eigerbio.com. For today's call, we will have prepared remarks from the management team, followed by Q&A. We will use slides for the webcast, and a replay will be available on the Investors section of our website.

Joining me on the call with prepared remarks are David Cory, President and CEO; Sri Ryali, Chief Financial Officer; Eldon Mayer, Chief Commercial Officer; and Dr. Ingrid Choong, Senior Vice President, Clinical Development. We also have subject matter experts from our team, Dr. Colin Hislop, Senior Vice President, Clinical and Development Operations; and Dr. Colleen Craig, Vice President, Metabolic Diseases available for Q&A.

Before we begin, I'd like to remind investors that this call will include forward-looking statements, including expectations concerning financial performance, commercial products and potential future products in different therapeutic areas and stages of development. The forward-looking statements rely on certain assumptions and involve risks and uncertainties beyond Eiger's control, which could cause our actual results to differ materially.

A description of these risks and uncertainties is contained in Eiger's filings with the SEC, including our latest 10-K and 10-Q reports available on the Eiger website in the Investors section. All forward-looking statements are based on information currently available to Eiger, and we assume no obligation to update these statements.

I'll now turn the call over to David.

David Cory

Thanks, Sarah. As we enter the second half of 2022, momentum continues to build across all of our programs with multiple upcoming value-creating milestones. These clearly position Eiger as a highly differentiated biopharmaceutical company with a diverse pipeline with major catalysts in our development programs for peginterferon lambda, lonafarnib and Avexitide as well as on the commercial front with Zokinvy, we believe that 2022 is shaping up to be a transformational year for Eiger.